Ascelia Pharma AB (ACE.ST)

Every figure this model derived for ACE.ST, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2024-12-31
cash 75,256,000 CashAndCashEquivalents 2025-01-01
current assets 83,718,000 CurrentAssets 2025-01-01
current liabilities 61,976,000 CurrentLiabilities 2025-01-01
equity 78,944,000 EquityAttributableToOwnersOfParent 2025-01-01
interest expense 13,942,000 FinanceCosts 2024-12-31
ocf -62,844,000 CashFlowsFromUsedInOperatingActivities 2024-12-31
revenue 0 Revenue 2024-12-31
sbc 4,340,000 AdjustmentsForSharebasedPayments 2024-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up ACE.ST on one particular measure came for.

RatioValue
current ratio1.35
current ratio reported1.35
interest cover-4.86
roic-1451.6

What to be careful about

What this model itself distrusts about ACE.ST's figures. Written by the derivation as it ran, not added afterwards.